GSK (GSK) Stock Forecast, Price Target & Predictions
GSK Stock Forecast
GSK stock forecast is as follows: an average price target of $58.00 (represents a 72.11% upside from GSK’s last price of $33.70) and a rating consensus of 'Hold', based on 11 wall street analysts offering a 1-year stock forecast.
GSK Price Target
GSK Analyst Ratings
Hold
GSK Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 02, 2024 | Peter Welford | Jefferies | - | - | 38.09% | 57.27% |
Apr 11, 2024 | Vamil Divan | Guggenheim | - | - | -11.53% | 6.82% |
Apr 11, 2024 | Mark Purcell | Morgan Stanley | - | - | 108.90% | 152.23% |
10
GSK Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 3 |
Avg Price Target | - | - | $58.00 |
Last Closing Price | $33.70 | $33.70 | $33.70 |
Upside/Downside | -100.00% | -100.00% | 72.11% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 15, 2024 | Deutsche Bank | Hold | Downgrade | |
Oct 31, 2024 | Guggenheim | Buy | Neutral | Downgrade |
Oct 07, 2024 | Jefferies | Buy | Buy | Hold |
Oct 01, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
Aug 12, 2024 | Jefferies | Buy | Buy | Hold |
Aug 12, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
Jul 22, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Jul 11, 2024 | Guggenheim | Buy | Buy | Hold |
Jul 08, 2024 | UBS | Neutral | Downgrade | |
Jul 02, 2024 | Jefferies | Buy | Buy | Hold |
10
GSK Financial Forecast
GSK Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | $6.95B | $7.38B | $7.83B | $6.93B | $9.78B | $9.53B | $9.08B | $8.09B | $7.42B | $8.74B | $8.65B | $7.62B | $9.09B | $8.90B | $9.38B | $7.81B | $7.66B |
Avg Forecast | $10.91B | $10.91B | $10.47B | $9.87B | $9.98B | $10.52B | $9.57B | $8.89B | $9.66B | $9.37B | $8.78B | $8.07B | $8.90B | $8.31B | $7.88B | $11.75B | $12.87B | $11.90B | $10.45B | $10.85B | $11.88B | $11.45B | $9.71B | $10.86B | $11.78B | $11.41B | $9.55B | $9.83B |
High Forecast | $11.07B | $11.07B | $10.62B | $10.01B | $10.24B | $10.67B | $9.71B | $9.02B | $9.70B | $9.52B | $8.91B | $8.19B | $9.03B | $8.31B | $7.88B | $11.75B | $12.87B | $11.90B | $10.45B | $10.85B | $11.88B | $11.45B | $9.71B | $10.86B | $11.78B | $11.41B | $9.55B | $9.83B |
Low Forecast | $10.70B | $10.69B | $10.26B | $9.67B | $9.72B | $10.31B | $9.38B | $8.71B | $9.62B | $9.23B | $8.61B | $7.91B | $8.72B | $8.31B | $7.88B | $11.75B | $12.87B | $11.90B | $10.45B | $10.85B | $11.88B | $11.45B | $9.71B | $10.86B | $11.78B | $11.41B | $9.55B | $9.83B |
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.86% | 0.83% | 0.94% | 0.88% | 0.83% | 0.74% | 0.76% | 0.77% | 0.68% | 0.74% | 0.76% | 0.79% | 0.84% | 0.76% | 0.82% | 0.82% | 0.78% |
Forecast
GSK EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | $2.75B | $1.90B | $2.17B | $1.73B | $3.51B | $1.74B | $2.93B | $2.36B | $2.08B | $3.71B | $2.51B | $2.87B | $2.26B | $1.20B | $2.71B | $2.28B | $2.70B |
Avg Forecast | $2.92B | $2.92B | $2.80B | $2.64B | $2.67B | $2.81B | $2.56B | $2.38B | $2.58B | $2.51B | $2.35B | $2.16B | $2.38B | $2.35B | $1.47B | $3.32B | $3.64B | $3.36B | $2.95B | $3.07B | $3.36B | $3.23B | $2.74B | $3.07B | $3.33B | $3.22B | $2.70B | $2.78B |
High Forecast | $2.96B | $2.96B | $2.84B | $2.68B | $2.74B | $2.85B | $2.60B | $2.41B | $2.59B | $2.55B | $2.38B | $2.19B | $2.42B | $2.35B | $1.77B | $3.32B | $3.64B | $3.36B | $2.95B | $3.07B | $3.36B | $3.23B | $2.74B | $3.07B | $3.33B | $3.22B | $2.70B | $2.78B |
Low Forecast | $2.86B | $2.86B | $2.74B | $2.59B | $2.60B | $2.76B | $2.51B | $2.33B | $2.57B | $2.47B | $2.30B | $2.11B | $2.33B | $2.35B | $1.18B | $3.32B | $3.64B | $3.36B | $2.95B | $3.07B | $3.36B | $3.23B | $2.74B | $3.07B | $3.33B | $3.22B | $2.70B | $2.78B |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.27% | 0.80% | 0.92% | 1.17% | 1.06% | 0.48% | 0.87% | 0.80% | 0.68% | 1.10% | 0.78% | 1.05% | 0.74% | 0.36% | 0.84% | 0.84% | 0.97% |
Forecast
GSK Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | $1.49B | $1.50B | $779.00M | $838.00M | $1.80B | $930.00M | $1.17B | $1.40B | $1.07B | $677.00M | $1.24B | $2.26B | $1.56B | $1.30B | $1.55B | $964.00M | $830.00M |
Avg Forecast | $1.27B | $2.06B | $1.95B | $1.92B | $829.73M | $1.76B | $1.58B | $1.50B | $1.19B | $1.87B | $1.44B | $1.37B | $907.07M | $3.35B | $677.29M | $2.48B | $2.03B | $2.42B | $1.63B | $1.78B | $1.94B | $2.55B | $1.66B | $2.64B | $2.14B | $2.81B | $2.08B | $2.14B |
High Forecast | $1.30B | $2.10B | $1.98B | $1.95B | $1.00B | $1.80B | $1.58B | $1.50B | $1.25B | $1.90B | $1.47B | $1.39B | $924.20M | $3.35B | $812.75M | $2.48B | $2.03B | $2.42B | $1.63B | $1.78B | $1.94B | $2.55B | $1.66B | $2.64B | $2.14B | $2.81B | $2.08B | $2.14B |
Low Forecast | $1.24B | $2.01B | $1.89B | $1.87B | $658.51M | $1.71B | $1.58B | $1.50B | $1.11B | $1.82B | $1.40B | $1.33B | $883.32M | $3.35B | $541.83M | $2.48B | $2.03B | $2.42B | $1.63B | $1.78B | $1.94B | $2.55B | $1.66B | $2.64B | $2.14B | $2.81B | $2.08B | $2.14B |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 1.65% | 0.23% | 1.24% | 0.73% | 0.46% | 0.48% | 0.85% | 0.60% | 0.35% | 0.49% | 1.36% | 0.59% | 0.61% | 0.55% | 0.46% | 0.39% |
Forecast
GSK SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | $2.14B | $2.44B | $2.06B | $2.07B | $2.84B | $3.26B | $2.65B | $2.64B | $2.43B | $3.16B | $2.67B | $2.71B | $2.92B | $3.44B | $2.89B | $2.59B | $2.48B |
Avg Forecast | $3.47B | $3.47B | $3.33B | $3.14B | $3.18B | $3.35B | $3.04B | $2.83B | $3.07B | $2.98B | $2.79B | $2.57B | $2.83B | $2.62B | $1.67B | $3.71B | $4.06B | $3.76B | $3.30B | $3.43B | $3.75B | $3.61B | $3.06B | $3.43B | $3.72B | $3.60B | $3.01B | $3.10B |
High Forecast | $3.52B | $3.52B | $3.38B | $3.18B | $3.26B | $3.39B | $3.09B | $2.87B | $3.09B | $3.03B | $2.83B | $2.60B | $2.87B | $2.62B | $2.00B | $3.71B | $4.06B | $3.76B | $3.30B | $3.43B | $3.75B | $3.61B | $3.06B | $3.43B | $3.72B | $3.60B | $3.01B | $3.10B |
Low Forecast | $3.40B | $3.40B | $3.26B | $3.08B | $3.09B | $3.28B | $2.98B | $2.77B | $3.06B | $2.94B | $2.74B | $2.51B | $2.77B | $2.62B | $1.34B | $3.71B | $4.06B | $3.76B | $3.30B | $3.43B | $3.75B | $3.61B | $3.06B | $3.43B | $3.72B | $3.60B | $3.01B | $3.10B |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.83% | 0.86% | 0.78% | 1.24% | 0.77% | 0.80% | 0.70% | 0.80% | 0.71% | 0.84% | 0.74% | 0.88% | 0.85% | 0.93% | 0.80% | 0.86% | 0.80% |
Forecast
GSK EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | - | - | - | - | $0.74 | $0.74 | $0.39 | $0.42 | $0.90 | $0.46 | $0.58 | $0.70 | $0.54 | $0.34 | $0.63 | $1.14 | $0.79 | $0.66 | $0.79 | $0.49 | $0.42 |
Avg Forecast | $0.62 | $1.01 | $0.95 | $0.94 | $0.41 | $0.86 | $0.77 | $0.73 | $0.58 | $0.92 | $0.71 | $0.67 | $0.44 | $0.81 | $0.53 | $0.60 | $0.49 | $0.59 | $0.40 | $0.43 | $0.47 | $0.62 | $0.40 | $0.64 | $0.52 | $0.68 | $0.50 | $0.52 |
High Forecast | $0.64 | $1.03 | $0.97 | $0.96 | $0.49 | $0.88 | $0.77 | $0.73 | $0.61 | $0.93 | $0.72 | $0.68 | $0.45 | $0.81 | $0.53 | $0.60 | $0.49 | $0.59 | $0.40 | $0.43 | $0.47 | $0.62 | $0.40 | $0.64 | $0.52 | $0.68 | $0.50 | $0.52 |
Low Forecast | $0.61 | $0.98 | $0.93 | $0.91 | $0.32 | $0.84 | $0.77 | $0.73 | $0.54 | $0.89 | $0.69 | $0.65 | $0.43 | $0.81 | $0.53 | $0.60 | $0.49 | $0.59 | $0.40 | $0.43 | $0.47 | $0.62 | $0.40 | $0.64 | $0.52 | $0.68 | $0.50 | $0.52 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.11% | 1.66% | 0.48% | 0.80% | 1.50% | 0.93% | 0.99% | 1.77% | 1.25% | 0.72% | 1.02% | 2.83% | 1.23% | 1.27% | 1.16% | 0.97% | 0.81% |
Forecast
GSK Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BIIB | Biogen | - | - | 75.05% | Buy |
GSK | GSK | - | - | 72.11% | Hold |
AZN | AstraZeneca | - | - | 30.72% | Buy |
MRK | Merck | - | - | 29.07% | Buy |
SNY | Sanofi | - | - | 19.55% | Buy |
JNJ | Johnson & Johnson | - | - | 15.20% | Buy |
BMY | Bristol-Myers Squibb Company | - | - | 12.48% | Hold |
NVS | Novartis | - | - | 12.02% | Hold |
AMGN | Amgen | - | - | 4.11% | Buy |
ABBV | AbbVie | - | - | 0.91% | Buy |
GILD | Gilead Sciences | - | - | -8.90% | Buy |